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Objective: Thromboembolic events can occur in up to 20% of patients with a left ventricular assist device. The
aggressive use of anticoagulation with newer continuous-flow devices has potentially increased the risk of post-
operative bleeding. The predecessor of the HeartMate II left ventricular assist device, the HeartMate XVE (Thor-
atec Corp, Pleasanton, Calif), was associated with an extremely low thromboembolic risk, even without
anticoagulation, because of its unique textured surfaces. Even though several areas of the HeartMate II are tex-
tured, a protocol was adopted for this new axial flow pump requiring long-term anticoagulation with warfarin. In
our study, we investigated whether the HeartMate II left ventricular assist device is associated with a similarly low
thromboembolic risk as the HeartMate XVE.
Methods:At our institution, 45 patients (mean age, 57.24 14.2 years) underwent implantation of the HeartMate
II; 30 underwent bridge-to-transplantation therapy, 7 underwent destination therapy, and 8 underwent left ven-
tricular assist device exchange for a failed XVE left ventricular assist device. Total duration of HeartMate II sup-
port was 352.13 patient-months (mean duration, 7.2  5.2 months). All 45 patients were treated postoperatively
with warfarin and aspirin. We recorded use of these 2 medications and monthly international normalized ratios.
Prospectively, we also monitored patients for any clinical thromboembolic events and for pump thrombus.
Results: Of our 45 study patients, 41 had a mean international normalized ratio of less than 2.0; of those 41 pa-
tients, 21 had a mean international normalized ratio of less than 1.6. Because of recurrent gastrointestinal bleeding
episodes, 7 patients discontinued warfarin for a total duration of 39.1 patient-months. During the entire period of
HeartMate II support, we noted 1 thromboembolic event. In addition, another patient had a suspected left ventric-
ular assist device pump thrombus that resolved with a high-intensity heparin anticoagulation protocol (interna-
tional normalized ratio, 1.3).
Conclusions: Our preliminary single-center analysis suggests that the HeartMate II is associated with an ex-
tremely low thromboembolic risk and with less stringent requirements for anticoagulation. Selected patients at
high risk for bleeding can be safely followed with either no or extremely low anticoagulation requirements for
prolonged periods.Left ventricular assist device (LVAD) therapy is an estab-
lished treatment modality for patients with refractory heart
failure.1 Most patients who have undergone LVAD implan-
tation as bridge-to-transplantation therapy in the United
States have been supported with pulsatile volume displace-
ment devices, such as the HeartMate XVE (Thoratec Corp,
Pleasanton, Calif), the Novacor LVAD (WorldHeart, Oak-
land, Calif), or the Thoratec VAD (Thoratec Corp).2-6 Suc-
cess with those devices for bridge-to-transplantation
therapy led to their successful use as an alternative to trans-
plantation (ie, as destination therapy).7 Those devices pro-
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survival rates, yet they do have significant constraints, in-
cluding the need for extensive surgical dissection, a large
body size requirement, a large-diameter percutaneous lead,
and audible pump operation. Even more important, their
long-term mechanical durability is limited, frequently re-
quiring reoperations for device exchange.
The new HeartMate II LVAD, which incorporates contin-
uous-flow rotary pump technology, represents the next gen-
eration of devices. Its focus is enhanced durability and
quality of life for extended periods of circulatory support.
A principal advantage of these new pumps is their small
size, thereby extending therapy to underserved patient pop-
ulations, including women and even some children; in addi-
tion, the HeartMate II is associated with minimal noise and
greater patient comfort.8,9 The simpler design of continuous-
flow, rotary pump technology promises greater long-term
mechanical reliability with a single moving part, the internal
rotor (Figures 1 and 2). The HeartMate II LVAD is one sev-
enth the size and one fourth the weight of the previous Heart-
Mate XVE. We report our initial experience with changes in
anticoagulation and in the risk of thromboembolism with theurgery c November 2008
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TAbbreviations and Acronyms
INR ¼ international normalized ratio
LVAD ¼ left ventricular assist device
PTT ¼ partial thromboplastin time
TIA ¼ transient ischemic attack
HeartMate II in 45 patients with end-stage heart failure at the
University of Minnesota Medical Center.
MATERIALS AND METHODS
HeartMate II
The HeartMate II consists of an internal blood pump with a percutaneous
lead that connects the pump to an external system driver and power source
(Figures 1 and 2). The pump has an implant volume of 63 mL and generates
up to 10 L/min of flow at a mean pressure of 100 mm Hg. Details of Heart-
mate II function and the surgical implant technique have been described in
detail elsewhere.8
Patients
From October 1, 2005, through May 31, 2007, a total of 45 patients
(mean age, 57.24  14.2 years) underwent HeartMate II implantation at
the University of Minnesota Medical Center (30 underwent bridge-to-trans-
plantation therapy, 7 underwent destination therapy, and 8 underwent
LVAD exchange for a failed XVE model). Total duration of LVAD support
was 352.1 patient-months (mean duration, 7.8  5.38 months). All 45 pa-
tients were treated postoperatively with warfarin and aspirin. We recorded
use of these 2 medications and monthly international normalized ratios
(INRs). We calculated the mean INR from the mean of all the INRs recorded
at monthly intervals for all patients receiving HeartMate II devices. Prospec-
tively, we also monitored patients for any of 3 categories of clinical throm-
boembolic events and for device thrombosis, as defined below.
Neurologic event. Such events included any new, temporary, or per-
manent focal or global neurologic deficits, such as transient ischemic attack
(TIA), metabolic encephalopathy, and seizure.
Stroke. A stroke is a neurologic deficit lasting more than 24 hours or last-
ing 24 hours or less if a brain-imaging study shows new infarction. A TIA is
a neurologic deficit lasting 24 hours or less if an imaging study shows no
evidence of new infarction.
Peripheral thromboembolic event. These events do not involve
the central nervous system. They include a thrombus or thromboembolism
in the pulmonary or systemic circulation confirmed by means of standard
clinical and laboratory testing, operative findings, or autopsy findings or
that requires empiric intervention.
Device thrombosis. This event entails any obstructive thrombus in
the device or its conduits that is associated with clinical symptoms of im-
paired pump performance (eg, level 0, none; level 1,<10% obstruction
[minimal]; level 2, 11% to 50% obstruction [moderate]; level 3,>50% ob-
struction [severe]; and level 4, 100% obstruction [extreme].
Anticoagulation. For our study, we agreed on this 6-step initial anti-
coagulation regimen as a guideline: (1) initiation of an intravenous infusion
of unfractionated heparin 12 to 24 hours after HeartMate II implantation or
at the point that thoracostomy tube drainage is less than 50 mL/h; (2) titra-
tion of the heparin infusion to a partial thromboplastin time (PTT) of 45 to
50 seconds for 24 hours after implantation; (3) titration of the heparin infu-
sion to a PTT goal of 50 to 60 seconds after 24 hours; (4) titration of the hep-
arin infusion to a PTT goal of 55 to 65 seconds after an additional 24 hours;
(5) initiation of antiplatelet therapy on postoperative day 2 to 3 with 81 mg
of aspirin daily; and (6) initiation of anticoagulation with warfarin on post-The Journal of Thoracic and Coperative day 3 to 5 and after removal of thoracostomy tubes, titrating the
dose to an INR of 2 to 3 and discontinuing heparin after obtaining a therapeu-
tic INR.
However, as a result of significant gastrointestinal bleeding in 4 patients
and delayed pericardial tamponade in 1 patient (among the first 14 patients),
we decided to stop using postoperative heparin in all subsequent patients.
Furthermore, we decided to initiate anticoagulation with warfarin (starting
from day 3), titrating the dose to an INR of 1.5 to 2.0.
Data Collection
After obtaining written informed patient consent and enrollment into the
study, we collected baseline and follow-up data, including patient character-
istics, results of blood chemistry analyses, hematologic findings, neurologic
status, and concomitant medications. After patients were discharged from
the hospital to home, they returned to our institution for follow-up, device
review, and general status assessment weekly for the first 4 weeks and
then monthly until the study end point. We recorded readmissions to the
hospital and patient adverse events (including suspected device malfunc-
tions) throughout the study as they occurred using standardized definitions.
FIGURE1. External view of the HeartMate II left ventricular assist device.
Reprinted with permission from Thoratec Corp.
FIGURE 2. Cross-sectional internal view of the HeartMate II left ventric-
ular assist device. Reprinted with permission from Thoratec Corp.ardiovascular Surgery c Volume 136, Number 5 1319
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All INRs recorded for each patient for each month were averaged to ob-
tain 1 mean value for each patient. Values are reported as means standard
deviations.
RESULTS
Patient Characteristics
Of our 45 study patients, 30 received the HeartMate II as
bridge-to-transplantation therapy, 7 received it as destina-
tion therapy, and 8 received it in exchange for a failed Heart-
Mate XVE model. The mean age of these patients was 57.24
 14.2 years (range, 26–79 years), with 33 men and 12
women. The mean age of the patients in the bridge-to-trans-
plantation group was 51.7  13.7 years, that in the destina-
tion therapy group was 73.0  3.1 years, and that in the
failed XVE group was 64.4  9.7 years. The cause of heart
failure was ischemic in 64.4% (n ¼ 29) and idiopathic in
31.1% (n ¼ 14) of all patients; 1 patient had doxorubicin
(Adriamycin)–induced cardiomyopathy, and another had
postpartum cardiomyopathy.
The overall mean duration of HeartMate II support was
7.2  5.2 months, the duration in the bridge-to-transplanta-
tion group was 6.9  4.9 months, the duration in the desti-
nation therapy group was 12.1  7.4 months, and the
duration in the XVE exchange group was 7.8 3.8 months.
The total duration of support for all patients was 352.13 pa-
tient-months.
Anticoagulation
Of our 45 study patients, 41 had a mean INR of less than
2.0; of those 41 patients, 21 had a mean INR of less than 1.6
(Figure 3). The mean INR for all 45 patients during follow-
up is shown in Figure 4. Because of recurrent gastrointesti-
nal bleeding episodes, 7 patients did not receive warfarin for
a total duration of 39 patient-months. Of those 7 patients, 1
has been off warfarin for a total of 12 months; 2 patients have
been off warfarin for 6 months. The mean INR of patients
receiving warfarin (after excluding those patients not receiv-
ing warfarin) was 1.7  0.2.
Thromboembolic Events
During the entire period of HeartMate II support, we
noted only 1 thromboembolic event (2.2%). At the
time of that event, the patient had an INR of 2.4. He un-
derwent immediate cerebral arteriography and intracere-
bral arterial lytic therapy (tissue plasminogen activator
and mechanical embolectomy), which allowed full recov-
ery. At the time of presentation of this thromboembolic
event, this patient underwent echocardiographic analysis,
which did not reveal any source of the thrombus. In ad-
dition, the patient’s LVAD pump parameters (including
the flow, power, and pulsatility index) did not show
any abnormalities. We did not change his anticoagulation
protocol; 6 weeks after this event, he was upgraded to1320 The Journal of Thoracic and Cardiovascular SUnited Network for Organ Sharing status IA. He subse-
quently underwent a heart transplantation and, as of the
end of this study, is doing well. In addition, 1 patient
also had postoperative paraplegia without any significant
recovery to date. The cause of this event is unknown. It
might have been related to this patient’s perioperative hy-
potension. She also had immediate right ventricular fail-
ure requiring temporary right ventricular assist device
support for 1 week after HeartMate II implantation with
a significant pressor requirement. Thus the overall inci-
dence of adverse neurologic events was 2 (4.4%) of
45. Note that no TIAs occurred in this group of Heart-
Mate II recipients. Also note that none of the patients
who discontinued warfarin experienced any thromboem-
bolic events during HeartMate II support.
FIGURE 3. Distribution of mean international normalized ratio (INR) in
HeartMate II recipients (n ¼ 45). LVAD, Left ventricular assist device.
FIGURE 4. Mean international normalized ratio (INR) during HeartMate
II left ventricular assist device (LVAD) support (n ¼ 45).urgery c November 2008
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Of the first 14 patients with the HeartMate II pump in our
series who received heparin followed by warfarin, 4 had gas-
trointestinal bleeding, and 1 had delayed pericardial tampo-
nade (5/14 [35.7%]). Of the remaining 31 patients who
received only warfarin and no heparin, 4 had gastrointestinal
bleeding, and none had pericardial tamponade (4/31
[12.9%]). Note that this analysis excluded patients who un-
derwent mediastinal exploration for bleeding on the day of
surgical intervention because that was unrelated to postoper-
ative anticoagulation therapy.
Device Thrombus
Of our 45 study patients, 1 had a suspected pump throm-
bus that resolved with a high-intensity heparin anticoagula-
tion protocol (INR, 1.3 at the time of presentation). This
patient had gone to an outside hospital with HeartMate II
flows in the mid-3 L/min range (in contrast to this patient’s
usual flows of>4 L/min) and with increased HeartMate II
power. After 12 hours of high-intensity anticoagulation hep-
arin therapy (PTT goal, 60–80 seconds), the patient’s hemo-
dynamic parameters returned to normal. Heparin therapy
was continued for 48 hours. Warfarin therapy was continued
to achieve an INR goal of 1.5 to 2.0. No thrombolytic ther-
apy was used. As of the end of this study, this patient is do-
ing well on the heart transplant waiting list without any
further similar episodes 6 months after this suspected
pump thrombus.
Thus, our overall incidence of device thrombus was 2
(4.4%) of 45, including 1 explanted pump that received
a thrombus score of 3, as reported in the next section.
Note that none of the patients who discontinued warfarin ex-
perienced any episodes of pump thrombus during HeartMate
II support.
Explanted Pump Analysis
For the 14 patients in our study group whose HeartMate II
was explanted (at the time of their heart transplantation), we
analyzed their explanted pumps for thrombus deposition. All
pumps except 1 received a thrombus score of 0 (none) or 1
(minimal). Figure 5 shows a typical photograph of an ex-
planted pump with no evidence of thrombus deposition at
the forward ruby bearing from a patient supported success-
fully by a HeartMate II for 164 days. The 1 explanted
pump that received a high score of 3 (>50% obstruction
with thrombus) had been in a patient who died after pro-
longed sepsis. He had several days of low pump flow preced-
ing his death, which might have been associated with the
development of pump thrombus.
DISCUSSION
The discrepancy between the limited availability of donor
organs and the ever-increasing number of patients with heartThe Journal of Thoracic and Cfailure has led to the increasing use of LVADs.10 The excel-
lent medium-term results with LVADs has led to the use of
permanent LVAD implantation for patients with end-stage
heart failure.7 Nevertheless, the clinical success of LVADs
has been accompanied by significant complications, includ-
ing thromboembolic events in as many as 30% of patients.
The development of novel materials used for implant
operations and the increasing use of implanted devices
has made it evident that no material is biologically inert.
Commonly used biomaterials, including so-called inert
compounds, such as titanium, polytetrafluoroethylene, and
acrylics, can trigger an array of iatrogenic effects, including
inflammation, fibrosis, coagulation, and infection. In the
case of LVADs, in which the biomaterial is in direct contact
with the blood circulation, significant changes in systemic
immunologic and thrombostatic functions have been well
documented. Like most other implanted devices, LVADs ac-
tivate the coagulation system, resulting in device-related
thrombus.11,12
The standard strategy to reduce the risk of thromboembo-
lism has been systemic anticoagulation. Despite this strat-
egy, the risk of thromboembolism continues to be as high
as 30%. Furthermore, the risk of bleeding after LVAD im-
plantation is exacerbated with anticoagulation.
The HeartMate II is a continuous-flow rotary LVAD com-
posed of a blood pump, a percutaneous lead, and an external
power source and system driver. The inlet and outlet cannu-
las include woven polyester grafts (CR Bard, Haverhill, Pa)
that require preclotting. The pump motor and associated
blood tube have smooth titanium surfaces; in an effort to du-
plicate the excellent biocompatibility of the original pulsatile
HeartMate XVE, the inlet and outlet elbows and the intra-
ventricular cannula are textured with titanium microsphere
coatings.8,9
FIGURE 5. Photograph of an explanted HeartMate II LVAD with no ev-
idence of thrombus deposition at the forward ruby bearing from a patient
supported successfully for 164 days.ardiovascular Surgery c Volume 136, Number 5 1321
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HeartMate XVE was that they would absorb and entrap ele-
ments from the patient’s blood to form a stable, densely ad-
herent biologic lining on the inside of the device.13-15 The
resultant tissue lining, rather than the underlying biomate-
rials, would then form the long-term blood-contacting inter-
face, thus obviating the need for systemic anticoagulation.
The HeartMate XVE actually encouraged the adherence of
a thin layer of fibrin-based neointima to its rough interior
surfaces, yet the risk of embolization was reduced by the
dense adherence of this acquired biologic lining to its sur-
face. The physiologic consequences of this biologic lining,
however, were many and varied because of the nature and
characteristics of the cells adhering to the HeartMate XVE
surface. Spanier and colleagues11,16 described a phenome-
non of a ‘‘compensated coagulopathy’’ underlying the ap-
parent autoanticoagulation in textured-surface HeartMate
XVE recipients, attributing this finding to procoagulant
stimuli elicited from the LVAD cell-surface environment.
Some investigators have suggested that such activation of
anticoagulation was due largely to the continuous contact
of blood with the foreign LVAD surface. However, others
showed that specific cells that progressively adhere to the
textured LVAD surface and become activated can also con-
tribute to the coagulopathy.14,16
In addition to the thromboembolic risks inherent with all
LVADs, including the HeartMate II, the left ventricle in pa-
tients with end-stage heart failure is also prone to the devel-
opment of thrombus in areas of pre-existing scar tissue, of
previous myocardial infarction, and of previous ventricular
aneurysm; such patients can even have a pre-existing throm-
bus. Thus they might already have an increased risk of
thromboembolism, even before LVAD implantation. More-
over, after LVAD implantation, the degree of blood stasis
in the patient’s heart is determined, in part, by the opening
of the native aortic valve. At our institution, we usually ad-
just the fixed-rate speed of the HeartMate II to maximize left
ventricular decompression and to improve cardiac output, si-
multaneously allowing for at least a 1:3 ratio of aortic valve
opening. We believe this adjustment has a favorable effect
on reducing the incidence of thromboembolism associated
with continuous-flow pumps, such as the HeartMate II.
In patients undergoing cardiopulmonary bypass, an asso-
ciation between a higher rate of microembolic signals during
cardiac surgery and postsurgical neurologic dysfunction has
been described.17,18 The clinical relevance of detecting mi-
croemboli is relatively unclear; this phenomenon is mostly
unrelated to the development of clinically significant ad-
verse neurologic events in patients receiving LVADs (in-
cluding HeartMate II).19-21 Whether routine surveillance
with transcranial Doppler monitoring confers a significant
clinical benefit remains unanswered.22
Our study was limited by its relatively small number of
single-center patients. Also, using the mean INR to represent1322 The Journal of Thoracic and Cardiovascular Surthe degree of anticoagulation might not truly capture the
level of anticoagulation accurately. It is certainly possible
that between patients’ monthly clinic visits, their levels of
anticoagulation might be higher or lower than what is shown
when the INR is being measured.
In conclusion, the new continuous-flow HeartMate II
LVAD has benefited from duplicating several features of
the original HeartMate XVE, especially in that both confer
a low thromboembolic risk. The explanation for the im-
proved thromboembolic rate most probably has more to do
with the influence of high pump flows, well-executed com-
putational fluid dynamics modeling, and the continuous-
flow nature of the device than with the textured surfaces.
The average flow in all 45 of our patients was consistently
greater than 4 L/min. Such high flow is associated with re-
duced stasis and with better washing effect and consequently
with a favorable effect on the risk of thrombus formation in
both the device pump and the patient’s heart. With increas-
ing experience, we have also successfully reduced the inten-
sity of anticoagulation (avoiding heparin and decreasing the
therapeutic INR, which formerly was 2.0–3.0 and now is
1.5–2.0), without any increased risk of thromboembolic
events. In addition, we currently treat patients with low-
dose warfarin therapy (2 to 3 mg/d) to achieve a therapeutic
INR of 1.5 to 2.0 by the end of the first week. The favorable
low thrombogenicity and thromboembolic risk associated
with the HeartMate II makes it well suited as destination
therapy. With the increasing number of adverse reactions
and the increasing intolerance to anticoagulation in the des-
tination therapy population, our experience with avoiding
anticoagulation (other than aspirin) in a select, albeit small,
number of patients receiving HeartMate II LVADs further
favors its use. Moreover, with the increasing number of
LVAD recipients who later undergo noncardiac surgery
(eg, hernia repairs and orthopedic procedures), the ability
to discontinue anticoagulation without a fear of thromboem-
bolic complications is paramount. Further studies are needed
that seek to identify the molecular and biochemical markers
of thromboembolism and bleeding to better understand
thromboembolic and bleeding risks in LVAD recipients.
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